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OBJECTIVE — Cross-sectional studies have reported increased levels of urinary type IV
collagenindiabeticpatientswithprogressionofdiabeticnephropathy.Theaimofthisstudywas
to determine the role of urinary type IV collagen in predicting development and progression of
early diabetic nephropathy and deterioration of renal function in a longitudinal study.
RESEARCH DESIGN AND METHODS — Japanese patients with type 2 diabetes (n 
254, 185 with normoalbuminuria and 69 with microalbuminuria) were enrolled in an observa-
tionalfollow-upstudy.TheassociationsofurinarytypeIVcollagenwithprogressionofnephrop-
athy and annual decline in estimated glomerular ﬁltration rate (eGFR) were evaluated.
RESULTS — At baseline, urinary type IV collagen levels were higher in patients with mi-
croalbuminuria than in those with normoalbuminuria and correlated with urinary 2-
microglobulin(0.57,P0.001),diastolicbloodpressure(0.15,P0.01),eGFR(
0.15, P  0.01), and urinary albumin excretion rate (0.13, P  0.01) as determined by
multivariate regression analysis. In the follow-up study (median duration 8 years), urinary type
IV collagen level at baseline was not associated with progression to a higher stage of diabetic
nephropathy.However,thelevelofurinarytypeIVcollageninverselycorrelatedwiththeannual
declineineGFR(0.34,P0.001).Multivariateregressionanalysisidentiﬁedurinarytype
IV collagen, eGFR at baseline, and hypertension as factors associated with the annual decline in
eGFR.
CONCLUSIONS — Our results indicate that high urinary excretion of type IV collagen is asso-
ciated with deterioration of renal function in type 2 diabetic patients without overt proteinuria.
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D
iabetic nephropathy is character-
ized structurally by accumulation
of mesangial matrix and thickening
ofthebasementmembraneintheglomer-
uli (1), as well as renal tubular hypertro-
phy and associated basement membrane
alterations in the tubulointerstitium,
which precede tubulointerstitial ﬁbrosis
(2). These abnormalities are associated
withrenaloverproductionoftheextracel-
lular matrix proteins such as type IV col-
lagen (3). We and others reported
previously that the production of type IV
collagen is enhanced in glomerular mes-
angial cells (4,5), podocytes (6), and
proximal tubular cells (7,8) cultured un-
der a high-glucose condition. Cross-
sectional studies reported a stepwise
increaseinurinarytypeIVcollagenexcre-
tion in diabetic patients, in parallel with
increased levels of urinary albumin (9–
14). Thus, a high level of urinary type IV
collagenhasbeenproposedasamarkerof
development and progression of early di-
abetic kidney disease. However, there is
little information on whether the increase
in type IV collagen excretion in urine is a
predictor of progression of diabetic ne-
phropathy or deterioration of renal func-
tion in type 2 diabetic patients.
The aim of this study was to deter-
minewhethertheurinarylevelsoftypeIV
collagen can predict the progression of
early diabetic kidney disease. For this
purpose, we conducted a prospective ob-
servational follow-up study involving
type 2 diabetic patients with normoalbu-
minuria and microalbuminuria and in-
vestigated the relationship between
urinary levels of type IV collagen and the
progressionofdiabeticnephropathystage
as well as the annual decline in estimated
glomerular ﬁltration rate (eGFR) during
the follow-up period.
RESEARCH DESIGN AND
METHODS— The participants with
type 2 diabetes were recruited from pa-
tientswhoregularlyvisitedtheoutpatient
clinic of the Department of Medicine,
Shiga University of Medical Science, be-
tween 1997 and 1999. Type 2 diabetes in
these patients had been diagnosed in ac-
cordance with the criteria of the World
Health Organization. Patients with can-
cer, liver disease, infectious disease, col-
lagen disease, and nondiabetic kidney
disease conﬁrmed by renal biopsy were
excluded from the study. In each of the
ﬁrst 2 years (baseline period), each indi-
vidual provided urine collected over a
24-h period once a year for the measure-
ments of urinary albumin excretion rate
(AER), blood samples for biochemical
measurements, and a spot urine sample
for type IV collagen. The serum and urine
samples were kept at 80°C if not ana-
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measurements of urinary AER by immu-
noturbidimetry assay (7070E; Hitachi
High-Technologies Co., Tokyo, Japan),
patients were classiﬁed according to dif-
ferent stages of nephropathy (regardless
of duration of diabetes) as having nor-
moalbuminuria (AER 20 g/min), mi-
croalbuminuria(20g/minAER200
g/min),orovertproteinuria(AER200
g/min) if the stages of the two annual
measurements were identical. Patients
who showed different stages of nephrop-
athy in the ﬁrst 2 years were excluded
fromthisstudy.Finally,254patientswith
normoalbuminuria (n  185) and mi-
croalbuminuria (n69) were enrolled in
this study. The participants underwent a
standardized clinical examination, bio-
chemicaltests,andameasurementofAER
in a 24-h urine collection once annually,
during the follow-up period. The fol-
low-up period lasted until the end of
2007 or death. The study protocol and
informed consent procedure were ap-
proved by the Ethics Committee of Shiga
University of Medical Science.
Measurement of urinary type IV
collagen
TheurinaryconcentrationsoftypeIVcol-
lagen were measured using a highly sen-
sitive one-step sandwich enzyme
immunoassay kit (Daiichi Fine Chemical
Co., Toyama, Japan). This assay uses two
monoclonal antibodies against the 7S do-
main and the triple helix domain of hu-
man placental type IV collagen (15). The
procedure was performed according to
the instruction provided by the manufac-
turer. The sensitivity of this assay is 0.8
ng/ml. The intra- and interassay coefﬁ-
cients of variation were 4.1 and 5.7%, re-
spectively. The urinary concentrations of
creatinine were simultaneously measured
by the Jaffe method. The urinary excre-
tion levels of type IV collagen were ex-
pressed as micrograms per gram of
creatinine.Thegeometricmeanofurinary
type IV collagen was used as the baseline
value of each individual for the analysis
because the levels of urinary type IV col-
lagen were measured twice in each
individual.
Deﬁnitions of outcome
Changes in the stage of diabetic nephrop-
athyrepresentedtransitionfromanystage
to a more advanced stage in 2-year con-
secutive measurements. Intermittent
transition to advanced stages in subjects
was not counted as progression. The an-
nual decline in eGFR over the course of
the study was determined from the slope
of the plot of all measurements of eGFR
for each individual (median 8 times;
range 3–9 times) calculated by linear re-
gression analysis and was expressed as
milliliters per minute per 1.73 m
2 per
year. In this study, eGFR was calculated
using the simpliﬁed prediction equation
proposed by the Japanese Society of Ne-
phrology (16): eGFR (milliliters per
minute per 1.73 m
2)  194  [age
(years)]
0.287  [serum creatinine (milli-
grams per deciliter)]
1.094  0.739 (for
females).Theserumconcentrationofcre-
atininewasmeasuredusingtheenzymatic
method.
Statistical analysis
Data are expressed as means 	 SD or me-
dians (interquartile range [IQR]). Cate-
gorical variables were compared between
two groups using the 

2 test, whereas the
unpairedStudent’sttestwasusedfornor-
mally distributed variables, and the
Mann-Whitney U test was used for vari-
ables with skewed distribution. For the
comparison among four groups, one-way
ANOVA with a Scheffe ´ test was used to
compare the differences between groups.
The Spearman correlation coefﬁcient was
used to analyze the association between
two variables. A multivariate regression
model with a stepwise forward method
wasappliedtoevaluatetheindependence
of factors, using logarithmic transformed
values of nonnormally distributed vari-
ables. Hypertension in this study was de-
ﬁned as blood pressure 140/90 mmHg
or current use of antihypertensive drugs.
The association of parameters considered
to be involved in the worsening of dia-
betic nephropathy was estimated using
the Kaplan-Meier procedure and was
compared by the log-rank test. The fol-
low-up time was censored if microalbu-
minuria developed or progressed or if the
patient was unavailable for follow-up. All
data were analyzed using SPSS (version
11;SPSS,Chicago,IL).P0.05wascon-
sidered statistically signiﬁcant.
RESULTS— Table 1 summarizes the
clinical characteristics of the participants
according to the stage of diabetic ne-
phropathy at baseline. The median level
of urinary type IV collagen in patients
with microalbuminuria was signiﬁcantly
higherthanthatinthosewithnormoalbu-
minuria. Univariate regression analysis
showed that urinary type IV collagen cor-
related with urinary 2-microglobulin
(Spearman coefﬁcient 0.55, P 
0.001) and weakly with AER (0.25,
P  0.001), systolic blood pressure (
0.18, P  0.01), diastolic blood pressure
(0.14, P  0.03), and triglycerides
(0.13,P0.03).Multivariateregres-
sion analysis with a stepwise forward
method identiﬁed log urinary 2-
Table1—Clinicalcharacteristicsofstudysubjectsatbaselineaccordingtothestageofdiabetic
nephropathy
Normoalbuminuria Microalbuminuria
n 185 69
Sex (male/female) 80/105 45/24*
Age (years) 60 	 96 2 	 7
Duration of diabetes (years) 13 	 81 4 	 7
BMI (kg/m
2) 23.1 	 3.4 24.1 	 2.9
A1C (%) 7.1 	 0.8 7.3 	 1.0
Diabetes treatment (diet/oral agents/insulin) 33/117/35 5/44/20*
Systolic blood pressure (mmHg) 133 	 15 137 	 16
Diastolic blood pressure (mmHg) 76 	 87 9 	 8
Hypertension (%) 47 68*
Taking renin-angiotensin system inhibitors (%) 15 26*
Total cholesterol (mg/dl) 216 	 29 206 	 25
Triglycerides (mg/dl) 97 (66–134) 106 (78–145)
HDL cholesterol (mg/dl) 60 (49–72) 53 (44–61)*
Urinary AER (g/min) 7.5 (5.3–10.1) 44 (33–66)*
eGFR (ml/min per 1.73 m
2) 84 	 15 80 	 14*
Urinary 2-microglobulin (g/g Cr) 125 (81–195) 138 (94–365)*
Urinary type IV collagen (g/g Cr) 5.96 (4.61–7.70) 7.47 (5.52–11.96)*
Data are mean 	 SD for normally distributed variables and median (25th–75th interquartiles) for skewed
variables unless otherwise indicated. *P  0.05 vs. normoalbuminuria.
Urinary type IV collagen and renal dysfunction
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astolic blood pressure (0.15, P 
0.01), eGFR (0.15, P  0.01), and
log AER (0.13, P  0.01) as signiﬁ-
cantindependentdeterminantsofloguri-
nary type IV collagen. Furthermore, the
level of urinary type IV collagen was
higher in patients with hypertension than
in normotensive subjects (7.27 g/g Cr
[IQR 5.38–9.49] vs. 5.78 g/g Cr [4.56–
7.34], P  0.001). Urinary type IV colla-
gen levels were not inﬂuenced by sex.
We explored the predictive effect of
urinary type IV collagen on worsening of
diabetic nephropathy. During the fol-
low-upperiod(median8years;range3–9
years), 16 of the 185 diabetic subjects
with normoalbuminuria and 9 of the 69
with microalbuminuria progressed to
more advanced stages of diabetic ne-
phropathy. Among subjects with nor-
moalbuminuria at baseline, urinary type
IV collagen levels were not different be-
tween those who progressed to mi-
croalbuminuria(6.04g/gCr[IQR4.73–
7.67 g/g Cr]) and those who did not
(5.62 g/g Cr [3.06–8.07 g/g Cr], P 
0.46, by Mann-Whitney U test). In con-
trast, the median urinary AER was signif-
icantly higher in those who progressed
(10.6g/min[8.0–13.0g/min])thanin
those who did not (7.1 g/min [5.1–9.8
g/min],P0.002).Amongthesubjects
with microalbuminuria, the urinary type
IV collagen level was not different be-
tween those who progressed to overt pro-
teinuria (5.52 g/g Cr [4.33–8.25 g/g
Cr]) and those who did not (7.68 g/g Cr
[5.86–12.21 g/g Cr], P  0.11),
whereas urinary AER tended to be different
inthesetwosubgroups(55.7[35.8–131.3]
vs. 42.9 g/min [31.9–64.5 g/min], re-
spectively,P0.07).Furthermore,urinary
type IV collagen above the median cutoff
point (6.36 g/g Cr) was neither pre-
dictive for future development of mi-
croalbuminuria in patients with
normoalbuminuria nor for progression to
overt proteinuria in those with mi-
croalbuminuria, as examined with the
Kaplan-Meier method (log-rank test: P 
0.90 for normoalbuminuria, P  0.84 for
microalbuminuria) (Fig. 1).
Next, we analyzed the relationship
between urinary type IV collagen and de-
terioration of renal function. Univariate
regression analysis showed that the level
of urinary type IV collagen inversely cor-
related with the annual decline in eGFR
(0.34,P0.001)(Fig.2),whereas
urinary AER correlated weakly with this
decline ( 0.14, P  0.03). Multivar-
iate regression analysis with a stepwise
forward method identiﬁed log urinary
typeIVcollagen(0.28,P0.001),
eGFR at baseline ( 0.18, P 
0.002), and hypertension ( 0.13,
P  0.03) as factors associated with the
annual decline in eGFR. When the pa-
tients were divided according to the me-
dian cutoff level of urinary type IV
collagen, the mean value of eGFR at the
endofstudywassigniﬁcantlylowerinthe
patients above the median cutoff level
(6.36 g/g Cr) than in those below the
median cutoff level (69.6 	 16.3 vs.
73.8 	 15.8 ml/min per 1.73 m
2; P 
0.039), whereas the mean value of eGFR
at baseline was not different in the two
subgroups (83.2 	 15.4 vs. 81.9 	 13.8
ml/min per 1.73 m
2; P  0.50). Interest-
ingly, those above the median cutoff level
showed a rapid decline of eGFR in the
follow-upcomparedwiththosewhowere
below (1.69 	 1.40 vs. 0.82 	 1.15
ml/min per 1.73 m
2/year; P  0.001). Fi-
nally, the annual decline in eGFR was
compared in four subgroups of patients
according to the stage of diabetic ne-
phropathy and the median cutoff level of
urinary type IV collagen (Fig. 3). In pa-
tients with normoalbuminuria, the an-
nual decline in eGFR was signiﬁcantly
larger in those with urinary type IV colla-
gen level above the median cutoff level
than in those with who were below the
median value. Similarly, the annual rate
in eGFR of those with microalbuminuria
and above the median cutoff value was
larger than that in those with normoalbu-
minuria below the median value, al-
though the annual decline in those with
Figure 1—Kaplan-Meier curves for development of microalbuminuria in patients with nor-
moalbuminuria (A) and progression of overt proteinuria in those with microalbuminuria (B)
grouped according to the median cutoff value of urinary type IV collagen level. The difference
betweentwosubgroupswascomparedbyalog-ranktest.——,patientsabovethevalue(6.36g/g
Cr; n  127);––– ,patients below the value (6.36 g/g Cr; n  127).
Figure 2—Correlation between urinary type IV collagen and annual decline in eGFR (Spearman
coefﬁcient   0.34, P  0.001). The log-transformed values of urinary type IV collagen were
used in this plot because the raw values showed a skewed distribution.
Araki and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 8, AUGUST 2010 1807microalbuminuria and below the median
value was not different.
CONCLUSIONS — The present
study showed that the level of urinary
type IV collagen was higher in patients
withmicroalbuminuriathaninthosewith
normoalbuminuria and correlated with
the level of urinary 2-microglobulin, di-
astolic blood pressure, eGFR, and AER at
baseline. In addition, the level of urinary
type IV collagen at baseline inversely cor-
related with the annual decline in eGFR
during the follow-up period (median 8
years), whereas these levels were not as-
sociated with worsening of the stage of
diabetic nephropathy. Furthermore, the
large annual decline in eGFR of patients
with increased urinary type IV collagen
excretion was observed regardless of the
stage of diabetic nephropathy.
In this study, the median level of uri-
nary type IV collagen was higher in dia-
betic patients with microalbuminuria
than in those with normoalbuminuria, in
agreement with previous studies (9–14).
Several cross-sectional studies reported
that a substantial number of diabetic pa-
tients with normoalbuminuria had high
levels of urinary type IV collagen (10,14).
Based on these results, it was proposed
that urinary type IV collagen could in-
crease before any increase in albuminuria
in diabetic patients and could be a useful
marker for the identiﬁcation of early
stages of diabetic nephropathy. However,
our follow-up study did not show any
predictive role of urinary type IV collagen
inthedevelopmentandprogressionofdi-
abetic nephropathy, although urinary
AER is a highly variable quantity. Our re-
sult suggests that the increase in urinary
type IV collagen in the diabetic patients
without overt proteinuria could be con-
sidered to reﬂect other renal damage pro-
cesses not directly related with the degree
of albuminuria.
A recent study identiﬁed patients
whose renal function deteriorated rapidly
without any increase in urinary albumin
excretion (17,18). In this study, the level
ofurinarytypeIVcollagenatbaselinecor-
related with the decline in eGFR during
the follow-up. This predictive power of
urinary type IV collagen was observed
even in patients with normoalbuminuria
as well as in those with microalbumin-
uria. Interestingly, multivariate regres-
sion analysis in this study showed that
urinary levels of type IV collagen corre-
lated with the levels of urinary 2-
microglobulin, in agreement with the
ﬁnding of a previous study (12). The in-
creaseinurinary2-microglobuliniscon-
sidered to be associated with impaired
renaltubularcellfunctionandamarkerof
renal tubulointerstitial injury. Okonogi et
al. (19) reported that urinary IV collagen
excretion in type 2 diabetic patients was
associatedwithhistopathologicalchanges
in glomeruli and tubulointerstitium. Al-
though diabetic nephropathy was tradi-
tionally considered to cause primarily
glomerular damage, it is now widely ac-
ceptedthatdeteriorationofrenalfunction
indiabeticpatientscorrelateswiththede-
gree of tubulointerstitial ﬁbrosis (20).
Taken together with these ﬁndings, in-
creased levels of urinary type IV collagen
could reﬂect the degree of renal impair-
ment associated with renal glomerular
andtubulointerstitialinjuries.Thus,mea-
surement of urinary type IV collagen may
be useful for the identiﬁcation of diabetic
patients whose renal function could de-
cline rapidly without worsening of
albuminuria.
Urinary type IV collagen levels did
not correlate with A1C levels in our pop-
ulation. This ﬁnding is in agreement with
those reported by two groups in Japanese
type 2 diabetic patients (11,19). Cohen et
al. (13) also reported no such correlation
in type 1 and 2 diabetic patients. These
results suggest that other factors apart
from hyperglycemia contribute to the in-
crease in urinary type IV collagen. In this
study, systolic and diastolic blood pres-
sure correlated weakly with urinary type
IV collagen; the latter was signiﬁcantly
higher in patients with hypertension than
in those without hypertension. Similarly,
Tomino et al. (14) reported signiﬁcant
correlations between urinary type IV col-
lagen and systolic and diastolic blood
pressure, but not with fasting glucose lev-
els, in an Asian multicenter study. Kota-
jima et al. (11) reported that urinary type
IV collagen was increased in hypertensive
type 2 diabetic patients at the 6-month
follow-up compared with baseline, but
did not increase in those without hyper-
tension. Thus, these results suggest that
urinary type IV collagen reﬂects the de-
gree of hypertension-related renal injury,
in addition to the abnormal metabolic
conditions in diabetic patients.
Our study has some limitations. Uri-
nary AER is highly variable and is not a
relatively reproducible quantity like
eGFR. In this study, we did not enroll the
patients whose stages of nephropathy in
two measurements of urinary AER at
baseline were not identical. These pa-
tients may rapidly progress to more ad-
vanced stages, and, thus, their inclusion
might underestimate the predictive
power of urinary type IV collagen on de-
velopment and progression of diabetic
nephropathy. In this study we did not
evaluate the time-dependent changes in
urinary type IV collagen levels during the
Figure3—AnnualdeclineineGFR.Subjectswerecategorizedasbeingaboveorbelowthemedian
cutoff of urinary type IV collagen level (6.36 g/g Cr) and urinary AER (20 g/min). NL,
patientswithnormoalbuminuriaandlessthanthemediancutoffvalueofurinarytypeIVcollagen
(n  103, 0.78 	 0.11 ml/min per 1.73 m
2/year); NH, patients with normoalbuminuria and
above the median cutoff value (n  82, 1.68 	 0.15 ml/min per 1.73 m
2/year); ML, patients
with microalbuminuria and less than the median cutoff value (n  24, 0.97 	 0.27 ml/min per
1.73m
2/year);MH,patientswithmicroalbuminuriaandabovethemediancutoffvalue(n45,
1.69 	 0.22 ml/min per 1.73 m
2/year). Data are mean 	 SEM. *P  0.01 vs. patients with
normoalbuminuria and below the median value (ANOVA with Scheffe ´ test).
Urinary type IV collagen and renal dysfunction
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type IV collagen could be modiﬁed by a
variety of medications (21). Recently, we
reported frequent remission of mi-
croalbuminuria in type 2 diabetic pa-
tients, which was associated with
improvement of cardiorenal outcome
(22). Also, the rapid annual decline in
eGFR in those with higher levels of uri-
nary type IV collagen may be due in part
to regression to the mean. Further studies
are required to determine whether the
urinary type IV collagen level is a suitable
therapeutic index of improving renal out-
comes. At this stage, the source of in-
creased urinary type IV collagen in
diabetic patients is unknown. Urinary
type IV collagen measured in this study is
considered to be the intact form with a
molecular weight of 540 kDa, which is
detected as a single peak in gel ﬁltration
analysis (23). Thus, it is unlikely that uri-
narytypeIVcollagenwasﬁlteredthrough
the glomeruli from blood in the early
stages of diabetic nephropathy. Upregu-
lation of type IV collagen in podocytes
(6), proximal tubular cells (7,8), and/or
inﬁltrating ﬁbroblasts in the tubulointer-
stitium (24) observed in diabetes may be
responsible for the increased urinary ex-
cretion. Furthermore, reduced degrada-
tionoftypeIVcollagenindiabetesmaybe
responsible for the increased excretion of
urinary type IV collagen (25).
In summary, the present study dem-
onstratedthatincreasedurinaryexcretion
of type IV collagen is a predictor of dete-
rioration of renal function rather than
progression of nephropathy in type 2 di-
abetic patients without overt proteinuria
and that this relationship may be associ-
ated with the degree of glomerular and
tubulointerstitialimpairment.Thus,mea-
surement of urinary type IV collagen may
be useful for the identiﬁcation of diabetic
patients without overt proteinuria who
have a higher risk for rapid deterioration
of renal function. Further intervention
study is required to clarify whether a re-
duction in urinary type IV collagen is
therapeuticallyusefulindiabeticpatients.
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